Chicago area family stranded in Dominican Republic after husband needs emergency brain surgery
The Dervis family joined about 30 other people from the Johnsburg area on a trip to the Dominican Republic — all of them celebrating their kids' recent graduation from Johnsburg High School. Now, the Dervises are trying desperately to figure out a way to get back to the United States — finding themselves stranded after her husband had to go in for brain surgery.
"I just want to go home," said Bonnie Dervis. "I just want to get to the United States. I just want to get medical treatment."
Dervis spoke to CBS News Chicago from a medical center outside of Punta Cana in the Dominican Republic. Far from the picture-perfect vacation she had planned with her husband, Greg, to celebrate the graduation of their son, Cole.
"It's really hard on Cole, because he feels bad, you know? He doesn't know what to do either. He feels bad," said Bonnie Dervis, "and then he's worried about me, because I'm alone in a different country all by myself."
Greg Dervis got sick on the trip, and was diagnosed with a blood clot in his brain.
"They had to remove the whole blood clot and part of his skull to reduce the swelling," said Bonnie Dervis. "He needed to go to the ICU, but the hospital wouldn't put him in ICU until I gave them $10,000."
Greg and Bonnie Dervis will be married 21 years in August. They work together at an HVAC repair company, and Bonnie said their insurance won't cover the overseas medical treatment — including the brain surgery.
"I needed $15,000 just to give them to do the brain surgery," said Bonnie Dervis. "Twenty-five grand total I've done so far right now."
Greg Dervis has been released from the ICU. He is talking and recognizes Bonnie. But doctors say due to swelling from the blood clot, he cannot get on a commercial flight for at least six weeks.
A family friend, JD Sylvanus, started an online fundraiser through GoFundMe, in an effort to cover medical expenses and get the couple back to Johnsburg. The GoFundMe said the family needs desperate help with ongoing hospital and medical expenses, temporary housing near the hospital, food and transportation, and support for the Dervises' 7-year-old daughter, Morgan, back home.
As of Monday night, the fundraiser had netted $14,495 out of a $25,000 goal.
"It's very heart-wrenching to try and tear yourself in two to be there for your family members," said Bonnie Dervis.
Both of the Dervis children are back with a family friend in Johnsburg.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
This Diet Helps Lower Dementia Risk, And We May Finally Know Why
The Mediterranean diet and others like it have been extensively linked to reducing the risk of disease, cognitive decline, and premature death. Now a new study provides more evidence that this choice of foods can protect against dementia – as well as giving us some clues as to why. A team from Rush University Medical Center in Chicago wanted to look specifically at the MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet, which combines elements of the Mediterranean diet with the DASH (Dietary Approaches to Stop Hypertension) diet. That's a lot of acronyms, but it essentially means lots of vegetables, whole grains, fish, and poultry, and not so much dairy, red meat, and fried food. Related: The researchers investigated links between this balance of food items and hippocampal sclerosis – a condition linked to dementia and Alzheimer's, where neurons die off in the brain's hippocampus. Analyzing the postmortem brains of 809 people for whom diet information had been logged for several years before their death, the study found that those who stuck closest to the MIND diet were less likely to show signs of hippocampal sclerosis. "These findings suggest that consuming a healthy diet, such as the MIND diet, may decrease the likelihood of hippocampal sclerosis and may support hippocampal health," write the researchers in their published paper. The diet's impact on dementia risk has been well established by prior research. This latest study offers fresh insight into a significant part of the reason why that link is there: the foods in the MIND diet appear to protect the hippocampus in particular. Crucial to remembering, learning, and navigating, damage to the hippocampus is closely tied to dementia. While not everyone with hippocampal sclerosis has dementia, or vice versa, there's a significant overlap between the two conditions. The research accounted for a variety of demographic and genetic factors, but isn't enough to prove direct cause and effect. What it does show, together with earlier studies, is a strong probability that dementia risk is to some extent affected by what we eat. "To our knowledge these are the first findings in human studies to report that the association of diet and dementia is partially mediated by hippocampal sclerosis," nutrition epidemiologist Puja Agarwal told Hannah Millington at Newsweek. It's not clear how hippocampal sclerosis gets started, but scientists are continuing to discover more about it, and its connections to dementia. It's not the first time it's been shown that the health of this part of the brain could be affected by diet. Future studies may endeavor to understand why this link exists. It's possible that the anti-inflammatory and antioxidant effects of the foods in the MIND diet are helping to guard the brain's neurons from damage in some way. "To further understand the mechanisms linking diet and nutrients with the overall brain health, investigating diet's relationship with other biomarkers of neuroinflammation and oxidative stress in the brain will be critical," write the researchers. The research has been published in JAMA Network Open. Related News A Signal of Future Alzheimer's Could Hide in The Way You Speak Something Inside Your Gut Could Be Like a Natural Ozempic New Vaccine For Two Deadly Cancers Shows Promise in Clinical Trial Solve the daily Crossword
Washington Post
11 hours ago
- Washington Post
It's not your imagination. Your period may be making your depression worse.
One in six women in the United States has depression, according to Centers for Disease Control and Prevention data based on a self-reported questionnaire. And new research seems to confirm what many suspect — the symptoms often can get worse just before your period. It's called premenstrual exacerbation (PME) of depression, and as many as 58 percent of people with depression who menstruate might have it, studies suggest. 'It could be they're experiencing premenstrual worsening of depressed sadness, or feelings of guilt or worthlessness, or loss of interest or pleasure,' said Jaclyn Ross, a licensed clinical psychologist at the Chicago Premenstrual Disorders Clinic. Most recently, a study published in BMJ Mental Health found that mood ratings were lowest from three days before until two days after their period in women with depression who tracked their symptoms. Premenstrual exacerbation of depression differs from the more commonly known premenstrual syndrome (PMS), which is characterized by physical symptoms such as aches, bloating and cramping, and emotional symptoms such as anxiety and mood swings, leading up to your period. However, both PME and PMS fall under the same 'umbrella of premenstrual emotional symptoms,' said Tory Eisenlohr-Moul, an associate professor of psychiatry and psychology at the University of Illinois Chicago College of Medicine, and a co-author of a study about PME published in the journal Biological Psychiatry in May. Premenstrual exacerbation of depression is easily confused with premenstrual dysphoric disorder (PMDD), a mood disorder that can also cause depression, anger and irritability around the middle of the menstrual cycle. The latter has been better-studied: In 2013, PMDD was included in the Diagnostic and Statistical Manual of Mental Disorders, or DSM-5, the reference book used by clinicians to define mental health conditions. The more important distinction, experts said, isn't so much symptom type or severity (both PME of depression and PMDD can be severe), but 'what happens during the follicular phase of the cycle,' Susan Kornstein, a professor of psychiatry and obstetrics & gynecology at Virginia Commonwealth University, wrote in an email. With PMDD, a person probably has no depressive symptoms in that follicular phase, which lasts from the first day of the new cycle until ovulation. Then, 'the symptoms turn on like a light switch,' Ross said, and, within a few days of menstruation, 'they turn off like a light switch.' On the other hand, PME 'is more like a dial,' she said. Because there's a preexisting condition — in this case, depression — 'symptoms are there all the time, but they turn up.' Official diagnostic criteria for PME don't exist — patients are diagnosed and treated based on the underlying disorder. 'Basically, PMDD was the cleaner alternative to create the diagnosis,' Eisenlohr-Moul said, 'but we know we have a lot of work to do to be more inclusive for people with messier symptom patterns.' Unlike PMDD, she said, PME 'is harder to see because you also have background things going on.' Just to make it all more complicated, Eisenlohr-Moul pointed out that a person might have PMDD then eventually develop chronic PME of depression. It's also possible to have both conditions, or symptoms that resemble PME but are something else entirely. Formally recognizing PME as a separate condition is a matter of some debate among experts, but its inclusion could open up more treatment options for patients, Eisenlohr-Moul pointed out. People with other psychiatric diagnoses may have symptoms that are exacerbated by the menstrual cycle. It's possible to experience PME 'of pretty much any mental health disorder,' Ross said, including obsessive-compulsive disorder, eating disorders and generalized anxiety disorder. With PME of depression, your symptoms tend to get worse during the luteal phase, seven to 14 days before your period, Eisenlohr-Moul said. You might feel intensely sad, or more fatigued or withdrawn than you do at other times in your cycle, according to the International Association for Premenstrual Disorders (IAPMD), a nonprofit that advocates for people with premenstrual conditions. Thoughts of self-harm and suicidality can also increase during this time. Symptoms usually return to their baseline after you get your period. The exact timing of symptoms can vary from month to month, though, 'which is so frustrating for scientists, clinicians and patients,' Ross noted. 'We want it to be neat and tidy.' Not all women with depression experience worse symptoms before their period. Although researchers have found you can have symptoms even if you're taking antidepressants. A common misconception is that PME is caused by hormonal imbalances. 'It's actually that you have an abnormal brain sensitivity to normal hormone fluctuations that happen across the menstrual cycle,' Ross said. 'The way I think of it is that your brain is allergic to your menstrual cycle.' Track your symptoms If your depression seems worse leading up to your period, start by writing down how you feel daily over the course of two menstrual cycles to look for patterns. Reporting back on symptoms from memory 'is not always reliable,' Kornstein said, 'which is why prospective daily charting is needed.' Eisenlohr-Moul recommended downloading the free symptom tracker worksheet on the IAPMD website. Connect with a provider who listens Your doctor should believe you if you tell them you're experiencing heightened depression around your period, then help monitor those symptoms to understand the impact they're having on your life. 'If a provider dismisses you or turns you away, find a new provider,' Eisenlohr-Moul said. Consider working with a therapist Ross recommended acceptance and commitment therapy (ACT), dialectical behavior therapy (DBT) or cognitive behavioral therapy (CBT) — 'all three of those contain elements that can be really useful for managing premenstrual symptoms.' Ideally, your therapist will work with you on tailoring coping skills to your cycle, she said, so you're better equipped on days you're most vulnerable. Ask about medication options Serotonin reuptake inhibitors (SSRIs) and birth control pills that contain drospirenone or ethinyl estradiol are approved to treat PPMD, but PME may require a different approach. Still, 'the frontline treatment for premenstrual emotional symptoms is SSRIs,' Ross said, so this can be 'a good place for people to start.' Some clinicians might prescribe an increased dose for high-symptom days. Oral contraceptives are also 'worth exploring as a potential treatment option' for PME, Ross added, 'although there's not a one-size-fits-all approach here.' (On the other hand, if you've already been taking oral contraceptives and are having exacerbated symptoms around your period, sometimes changing them may help, said Veerle Bergink, a professor in psychiatry and the director of Mount Sinai's Women's Mental Health Center.) On good days, follow a routine Sleep, diet and exercise aren't going to cure depression, experts stressed. (And implying that 'can be really discouraging and invalidating for people,' Ross noted.) But establishing positive lifestyle strategies might make harder days easier to manage. 'One of the things I hear patients talk about a lot is going into 'rotting' mode in bed,' Ross said. 'Maybe when I feel good in my follicular phase, maybe I run every day. That's not going to happen during the high-symptom phase, but could I still go for a 20- minute walk?' Catherine Monk, a clinical psychologist and the Diana Vagelos Professor of Women's Mental Health in obstetrics & gynecology at Columbia University, suggested making a list of calming activities you love, then trying to do at least one on high-symptom days: 'Not that it's going to make you feel fantastic, but it can help.' Establish a safety plan While not everyone with PMDD or PME of depression will have life-threatening thoughts, studies show that women with premenstrual disorders may have higher risk of self-harm. In a 2024 study published in the American Journal of Psychiatry, Ross, Eisenlohr-Moul and other researchers found that the menstrual cycle could worsen suicidal ideation and planning among psychiatric outpatients who'd had suicidal thoughts in the month prior. If your symptoms become severe, work with your medical team to put a safety plan into action on high-symptom days, Monk said. Most importantly, no one experiencing depression should suffer in silence, they said. Regardless of whether your depression is chronic, then gets worse around your period, or only appears leading up to menstruation, help is available. 'We don't want to contribute to this idea that all women have PMS, or all women with depression are depressed because of their hormones,' Eisenlohr-Moul said. 'Having said that, if you are a woman with depression, you are at greater risk of having these hormone sensitivity changes, and it makes sense to track and see if you are one of those people.' If you or someone you know needs help, call 988 or visit
Yahoo
a day ago
- Yahoo
Zacks Industry Outlook Highlights Envista, BioLife Solutions, InfuSystems and MariMed
For Immediate Release Chicago, IL – August 15, 2025 – Today, Zacks Equity Research discusses Envista Holdings NVST, BioLife Solutions BLFS, InfuSystems Holdings INFU and MariMed MRMD. Industry: Medical Products Link: The Zacks Medical - Products industry is likely to remain under pressure through the rest of 2025. While procedural volumes are stable, growth is slowing and high-cost, advanced procedures face adoption and funding hurdles. Capital spending is uneven, with longer sales cycles and reliance on expensive technologies creating risks. Innovation in electrophysiology, structural heart, and AI imaging is struggling to translate into consistent revenues amid regulatory delays, competition and payer scrutiny. Emerging markets face policy headwinds, notably China's margin-eroding volume-based procurement. Tariffs, component shortages, COVID testing declines and product discontinuations are further squeezing margins. Without a clear demand rebound or easing cost pressures, the risks led to continued underperformance for the sector. However, industry participants, such as Envista Holdings, BioLife Solutions, InfuSystems Holdings and MariMed, have adapted to changing consumer preferences, and most of them are witnessing a rise in their share price. These companies also carry a favorable Zacks Rank. Industry Description The industry includes companies that provide medical products and cutting-edge technologies for healthcare services. These companies are primarily focused on research and development and cater to vital therapeutic areas like cardiovascular, nephrology and urology devices. The increase in procedure volumes is driving sales, particularly for surgical products and services. At the same time, cost-cutting measures are helping companies improve their bottom-line performance. However, the industry's profitability picture is under significant strain. Tariff-related expenses are cutting into margins, forcing companies into complex and costly supply-chain restructuring. Persistent component shortages, though less widespread than in prior years, continue to create inefficiencies and constrain output in certain product lines. Additionally, the sharp drop in COVID-relate Major Trends Shaping the Future of the Medical Products Industry AI, Medical Mechatronics & Robotics: The increasing adoption of minimally invasive, robot-assisted surgeries, automated home care, IT-driven patient management, and value-based payment models underscores the rising influence of AI in the Medical Products sector. At the forefront is mechatronics — a fusion of electronics, machine learning, and mechanical engineering — driving innovation across the industry. Companies are making significant progress in AI, robotics, and medical mechatronics, with robotic surgical platforms enabling less invasive procedures and reducing patient trauma. Meanwhile, 3D printing is reshaping the landscape, now used to produce stem cells, blood vessels, heart tissue, prosthetics and skin. These advances highlight the sector's transformative shift toward precision, personalization and improved clinical outcomes. Rising Demand for IVD: The COVID-19 pandemic led to a rise in global demand for diagnostic testing kits to curb the spread of the virus. Testing became a pressing need, leading to a shift in the IVD product pipeline, with many rapid, point-of-care devices entering development. Diagnostic kit manufacturers not only received emergency use authorization from the FDA but also bolstered production to help address testing shortages. Industry players anticipate significant demand for rapid diagnostic testing in the future and are poised to capitalize on this opportunity. Emerging Markets Hold Promise: Driven by growing medical awareness and rising economic prosperity, emerging economies are experiencing strong demand for medical products. Factors such as aging populations, more relaxed regulatory environments, affordable skilled labor, increasing household wealth, and government investment in healthcare infrastructure make these markets highly attractive to global medical device companies. Zacks Industry Rank The Zacks Medical Products industry falls within the broader Zacks Medicalsector. It currently carries a Zacks Industry Rank #149, which places it in the bottom 39% of more than 250 Zacks industries. The group's Zacks Industry Rank, which is basically the average of the Zacks Rank of all member stocks, indicates bright near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Before we present a few medical product stocks that you may want to consider for your portfolio, let's take a look at the industry's recent stock-market performance and valuation picture. Industry Performance While the industry has outperformed its own sector, it has underperformed the Zacks S&P 500 composite in the past year. Stocks in this industry have collectively risen 5.1% against the Zacks Medical sector's decline of 19.9%. The S&P 500 has increased 17.2% in the same time frame. Industry's Current Valuation On the basis of the forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 21.4X compared with the S&P 500's 22.9X and the sector's 18.5X. Over the past five years, the industry has traded as high as 27.4X and as low as 17.9X, with the median being at 22X. 4 Promising Medical Product Stocks Envista Holdings enters the second half of 2025 with momentum from a solid first-half performance, supported by diversified growth across equipment, consumables, and specialty products. Continued strength in orthodontics, particularly Brackets & Wires and Spark Clear Aligners, will be augmented by product launches like Spark Retainers, AI-enhanced DTX Studio Clinic and Implant Direct scanning solutions. Penetration into dental service organizations (DSOs) and double-digit growth in emerging markets remain key levers. Operational improvements, including a 15% G&A reduction and manufacturing expansion in Suzhou, China, support margin resilience and local-for-local supply strategies. Pricing actions and cost controls are expected to offset tariff pressures, while acquisitions add incremental growth. Strong demand in infection prevention, diagnostics, and implants should continue, with the third quarter benefiting from Spark Deferral revenue. Stable dental market conditions, coupled with strategic investments in sales, marketing, and R&D, position Envista to deliver on its raised guidance for 2025. For this Brea, CA-based company, the Zacks Consensus Estimate for 2025 revenues is pinned at $2.61 billion. The consensus estimate for earnings is pegged at $1.12 per share. NVST delivered a trailing four-quarter average negative earnings surprise of 16.50%. Presently, the company sports a Zacks Rank #1 (Strong Buy). BioLife Solution is set to benefit from strong demand recovery in cell and gene therapy (CGT) tools, as customer manufacturing activity continues to normalize. The recent integration of Astero, Sexton, and other acquired technologies expands its bioproduction solutions portfolio, allowing deeper penetration into high-growth biopharma segments. Expansion of the cryo-storage services footprint, particularly through the SciSafe network, positions the company to capture more recurring revenues. Efforts to optimize manufacturing capacity and reduce COGS should support margin expansion. New product launches in media and biopreservation, alongside an expanded international sales presence, will help address broader customer needs. Strategic partnerships with therapy developers are expected to drive higher adoption of integrated workflow solutions. While macro uncertainty and biotech funding volatility remain potential headwinds, BioLife's diversified portfolio, operational efficiencies and exposure to commercial-stage CGT programs provide a solid foundation for growth through year-end. For this Bothell, WA-based company, the Zacks Consensus Estimate for 2025 revenues indicates a year-over-year decline of 11.7%. The consensus estimate for earnings indicates growth of 171.4%. It delivered a trailing four-quarter earnings surprise of 123.61%, on average. Presently, the company sports a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here. InfuSystem Holdings' growth trajectory in the second half of 2025 is anchored in its Device Solutions and Patient Services segments. Expansion of oncology and wound care programs, coupled with growing demand for infusion pumps and related disposables, is expected to lift volumes. The company is capitalizing on the broader adoption of negative pressure wound therapy (NPWT) through partnerships with large healthcare providers. A stronger equipment rental base and fleet optimization efforts should further enhance recurring revenue streams. INFU is also investing in service coverage expansion and technology upgrades to improve customer experience and retention. Operational efficiencies from centralized distribution and maintenance hubs are set to reduce turnaround times and lower costs. The integration of new payer contracts and an expanding referral network will support top-line growth. Risks include reimbursement changes and hospital capital spending constraints, but INFU's recurring revenue model and expanding therapeutic reach are positioned to offset these pressures in the near term. Currently, INFU sports a Zacks Rank of 1. For this Rochester Hills, MI-based company, the Zacks Consensus Estimate for 2025 revenues is pegged at $144.2 million. The consensus mark for loss is pinned at 26 cents per share. The company delivered a trailing four-quarter average earnings surprise of 79.17%. MariMed's growth in the remainder of 2025 will be driven by retail expansion, wholesale penetration and new product innovation in the cannabis sector. The opening of new dispensaries in high-traffic markets, along with remodeling existing locations to improve customer flow, is expected to boost sales. The company is scaling cultivation capacity and optimizing yields to meet growing demand while lowering production costs. Expansion of branded product lines, including edibles and wellness offerings, should strengthen shelf presence and margins. Wholesale growth is supported by increasing distribution agreements across multiple states. Investments in automation and processing technology aim to improve consistency and efficiency. Regulatory developments in key states, particularly around adult-use legalization, could provide an upside catalyst. While the industry faces pricing pressure and regulatory uncertainty, MariMed's vertically integrated model, brand strength, and disciplined capital allocation are set to underpin growth in the second half of the year. Currently, MRMD sports a Zacks Rank #1. For this Springfield, MA-based company, the Zacks Consensus Estimate for 2025 loss is pinned at 3 cents per share. The company delivered a trailing four-quarter average earnings surprise of 50.00%. Free: Instant Access to Zacks' Market-Crushing Strategies Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached. Get all the details here >> Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioLife Solutions, Inc. (BLFS) : Free Stock Analysis Report InfuSystems Holdings, Inc. (INFU) : Free Stock Analysis Report Envista Holdings Corporation (NVST) : Free Stock Analysis Report MariMed Inc. (MRMD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
